45 withdrawn. 45 Phase 3, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 45 | Withdrawn 45 |
| Phase 2 | 14 | Withdrawn 14 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer Capecitabine, Oxaliplatin, Fluorouracil - Colon Cancer Stage III | Phase 3 | Withdrawn | Johannes Laengle, MD, PhD | 2024-12-01 | 2024-09-20 | |
| Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer Nimotuzumab injection, Placebo, Trifluridine/tipiracil - Refractory Metastatic Colorectal Cancer | Phase 3 | Withdrawn | Biotech Pharmaceutical Co., Ltd. | 2024-04-03 | 2026-10-05 | |
| Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma Sitravatinib, Tislelizumab, sitravatinib-matching placebo - Hepatocellular Carcinoma | Phase 3 | Withdrawn | BeiGene | 2023-06-30 | 2023-06-07 | |
| A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC HLX10, HLX04, Sorafenib - Hepatocellular Carcinoma (HCC) | Phase 3 | Withdrawn | Shanghai Henlius Biotech | 2022-11-15 | 2022-05-05 | |
| Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer Metabolic treatment - Cancer, Overall Survival | Phase 3 | Withdrawn | Health Clinics Limited | 2022-05-23 | 2022-07-18 | |
| An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer Methylnaltrexone bromide (MNTX) - Pancreatic Cancer | Phase 3 | Withdrawn | Bausch Health Americas, Inc. | 2020-02-03 | 2021-05-07 | |
| A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer Methylnaltrexone bromide, Placebo - Pancreatic Cancer | Phase 2 / Phase 3 | Withdrawn | Bausch Health Americas, Inc. | 2020-01-06 | 2021-05-07 | |
| Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection Lenvatinib, Nivolumab - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Withdrawn | Shi Ming | 2019-10-30 | 2020-01-09 | |
| HepATocellular Cancer Hcv Therapy Study Elbasvir / Grazoprevir Oral Tablet - Hepatocellular Carcinoma, Hepatoma | Phase 3 | Withdrawn | Bayside Health | 2019-09-01 | 2020-09-14 | |
| Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC Lenvatinib, PD-1 antibody, Placebo - Hepatocellular Carcinoma | Phase 3 | Withdrawn | Sun Yat-sen University | 2019-04-21 | 2019-05-02 | |
| Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer Capecitabine, Cisplatin, Gemcitabine - Stage I Gallbladder Cancer AJCC v8, Stage II Gallbladder Cancer AJCC v8 | Phase 3 | Withdrawn | Emory University | 2019-04-03 | 2020-06-05 | |
| Sym004 Versus TAS-102 in Patients With mCRC Sym004, TAS-102 - Metastatic Colorectal Cancer, Colorectal Cancer Metastatic | Phase 3 | Withdrawn | Symphogen A/S | 2019-02-01 | 2019-02-04 | |
| First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study Pembrolizumab, Placebo, Cisplatin - Esophageal Neoplasms | Phase 3 | Withdrawn | Merck Sharp & Dohme LLC | 2019-01-21 | 2020-02-11 | |
| Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria Lenvatinib, PD-1 antibody, TACE - Hepatocellular Carcinoma | Phase 3 | Withdrawn | Sun Yat-sen University | 2019-01-01 | 2019-05-02 | |
| Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension Pembrolizumab, Cisplatin, 5-fluorouracil - Stomach Neoplasms | Phase 3 | Withdrawn | Merck Sharp & Dohme LLC | 2018-11-08 | 2021-12-16 | |
| Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients Probiotic Formula Capsule, Control - Colorectal Cancer | Phase 2 / Phase 3 | Withdrawn | King Hussein Cancer Center | 2018-11-07 | 2023-03-15 | |
| Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma HTP treatment - Pancreatic Adenocarcinoma, Pancreatic Cancer | Phase 3 | Withdrawn | Istituto Clinico Humanitas | 2018-07-12 | 2021-03-19 | |
| AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer AlloStim®, cryoablation, Physician's Choice (PC) - Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Withdrawn | Mirror Biologics, Inc. | 2017-12-01 | 2020-01-22 | |
| Low-dose Aspirin Therapy for Esophageal Cancer Acetylsalicylic acid - Esophageal Cancer | Phase 3 | Withdrawn | Zhejiang University | 2016-03-01 | 2021-04-27 | |
| Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB. S-1 for 6 months, S-1 for 1 year - Gastric Cancer | Phase 3 | Withdrawn | Fudan University | 2016-03-01 | 2019-05-08 |
Showing 20 of 45. Sign in to see all of them.
Carcinoma, Hepatocellular (15) · Colorectal Neoplasms (10) · Colonic Neoplasms (5) · Pancreatic Neoplasms (5) · Stomach Neoplasms (5) · Esophageal Neoplasms (3) · Bile Duct Neoplasms (2) · Gallbladder Neoplasms (2) · Neoplasm Metastasis (2) · Adenomatous Polyposis Coli (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Colonic Polyps (1) · Esophageal Squamous Cell Carcinoma (1)
Digestive System Diseases (45) · Neoplasms by Site (45) · Neoplasms (44) · Gastrointestinal Diseases (23) · Gastrointestinal Neoplasms (22) · Neoplasms by Histologic Type (18) · Neoplasms, Glandular and Epithelial (18) · Carcinoma (16) · Adenocarcinoma (15) · Liver Diseases (15) · Liver Neoplasms (15) · Colonic Diseases (14) · Intestinal Diseases (14) · Intestinal Neoplasms (14)
Fluorouracil (9) · Oxaliplatin (8) · Cisplatin (6) · Capecitabine (5) · Gemcitabine (5) · Leucovorin (5) · Folfox protocol (3) · lenvatinib (3) · Bevacizumab (2) · Sorafenib (2) · Surgical Procedures, Operative (2) · methylnaltrexone (2) · nimotuzumab (2) · pembrolizumab (2) · spartalizumab (2)
Guangxi Medical University (4) · Bausch Health Americas, Inc. (2) · Merck Sharp & Dohme LLC (2) · Samsung Medical Center (2) · Sun Yat-sen University (2) · Accuray Incorporated (1) · Albert Koong (1) · Antonios Likourezos (1) · Asan Medical Center (1) · Bayside Health (1) · BeiGene (1) · Biotech Pharmaceutical Co., Ltd. (1) · British Columbia Cancer Agency (1) · Cancer Prevention Pharmaceuticals, Inc. (1) · Centers for Disease Control and Prevention (1)
China (11) · United States (8) · South Korea (5) · Canada (2) · Austria (1) · Italy (1) · Jordan (1) · Thailand (1) · United Kingdom (1)
Lequn Li, PhD (3) · Ming Shi, MD (3) · John Lahey (2) · Albert Koong (1) · Albert Koong, MD, PhD (1) · Alfred M. Cohen, M.D. (1) · Bernard Nordlinger, Pr. (1) · Charlie Nutting, DO (1) · Daniel Chang, MD (1) · Danny Sherwinter, MD (1) · Dennis Carter, MD (1) · Fawzi Abuhijla, MD,MSc (1)
2018 (2), 2017 (1), P30CA042014 (1), R01CA080852 (1)